Stock listing
NASDAQ:RAIN Rain Oncology Inc Stock
Follow Rain Oncology Inc into a list and get an email when it puts out news.
Last close · NASDAQ:RAIN
$1.21 USD
Close on Jan 26, 2024 · No longer trades
- Lowest – highest close
- $0.822 – $20.91 USDSince Apr 23, 2021 · lowest Sep 15, 2023 · highest Jul 12, 2021
Delisted NASDAQ:RAIN no longer trades. Its last trading date is unknown. Company history and updates stay available on this page.
- Ticker
- NASDAQ:RAIN
- Asset type
- Stock
- Exchange
- NASDAQ
- Currency
- USD
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2026 | Nov 16, 2026 | +41.3% |
| Quarter to Jun 30, 2026 | Aug 14, 2026 | −9.2% |
| Quarter to Sep 30, 2025 | Nov 13, 2025 | +18.1% |
| Quarter to Jun 30, 2025 | Aug 14, 2025 | −6.3% |
| Quarter to Mar 31, 2025 | May 15, 2025 | +19.2% |
| Quarter to Mar 31, 2024 | May 21, 2024 | |
| Quarter to Dec 31, 2023 | Feb 29, 2024 | |
| Quarter to Sep 30, 2023 | Nov 9, 2023 | |
| Quarter to Jun 30, 2023 | Aug 10, 2023 | |
| Quarter to Mar 31, 2023 | May 11, 2023 |
All 18 quarters
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Dec 31, 2022 | Mar 9, 2023 | |
| Quarter to Sep 30, 2022 | Nov 10, 2022 | |
| Quarter to Jun 30, 2022 | Aug 4, 2022 | |
| Quarter to Mar 31, 2022 | May 4, 2022 | |
| Quarter to Dec 31, 2021 | Mar 3, 2022 | |
| Quarter to Sep 30, 2021 | Nov 10, 2021 | |
| Quarter to Jun 30, 2021 | Aug 10, 2021 | |
| Quarter to Mar 31, 2021 | Apr 2, 2021 |
Cap table
Built by 6ix from Rain Oncology Inc’s releases
- Common shares
- 11,646,299
- Fully diluted
- 11,646,299
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 11,646,299 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 11,646,299 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Franklin Berger Other companies: Retension Pharmaceuticals, Inc. (Director · Since at least Oct 13, 2026); Atea Pharmaceuticals, Inc. (Director · Since at least Oct 29, 2020); ESSA Pharma Inc (Director · Since at least Oct 1, 2020); Kezar Life Sciences, Inc. (Director · Since at least Jun 25, 2019); Kineta Inc. (Director · Jun 27, 2019 – Jun 29, 2020 · Past); Atreca Inc (Director · Jun 19, 2019 – Jun 13, 2023 · Past); Five Prime Therapeutics Inc (Director · Jun 10, 2019 – Apr 16, 2021 · Past); Tocagen Inc (Director · May 29, 2019 – Oct 4, 2019 · Past); Immune Design Corp (Director · Apr 2, 2019 – Apr 2, 2019 · Past) | Director · Apr 22, 2021 – Jan 26, 2024 · Past |
| Mark N Lampert Other companies: Immunic, Inc. (Director · Since at least Feb 17, 2026); Kymera Therapeutics, Inc. (Director · Since at least Jan 11, 2023); Olema Pharmaceuticals, Inc. (Director · Since at least Jun 10, 2022); MoonLake Immunotherapeutics (Director · Since at least Apr 5, 2022); CTi Biopharma Corp (Director · Aug 9, 2022 – Jun 26, 2023 · Past) | Director · Nov 8, 2022 – Jan 25, 2024 · Past |
| Aaron I Davis Other companies: Tango Therapeutics, Inc. (Director · Jun 8, 2022 – Aug 11, 2023 · Past); Iteos Therapeutics Inc (Director · Jul 23, 2020 – Jun 11, 2024 · Past) | Director · Apr 22, 2021 – Jan 26, 2024 · Past |
| Gorjan Hrustanovic Other companies: Kymera Therapeutics, Inc. (Director · Since at least Jun 16, 2021); Olema Pharmaceuticals, Inc. (Director · Since at least Nov 18, 2020) | Director · Apr 22, 2021 – Jan 26, 2024 · Past |
| Peter Radovich Other companies: Mirum Pharmaceuticals, Inc. (PRESIDENT AND COO · Since at least May 10, 2022) | Director · Jun 1, 2022 – Jan 26, 2024 · Past |
| Josephine Bruce | Principal Fin. & Acc. Officer · Jun 1, 2023 – Aug 9, 2023 · Past |
Log in to ask 6ix AI your own questions about Rain Oncology Inc.